Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Dyhia Houyou"'
Autor:
Louise Laloi, Natacha Chaumard Billotey, Pierre‐Yves Dumas, Franciane Paul, Alban Villate, Célestine Simand, Luc Fornecker, Florent Puisset, Sarah Bertoli, Marion Boissard Simonet, Kamel Laribi, Dyhia Houyou, Alberto Santagostino, Claire Michel, Gabrielle Roth Guepin, Elodie Guerineau, Reza Tabrizi, Mathilde Hunault, Aurélien Giltat, Eléonore Kaphan, Claude Bulabois, Elodie Cartet, Clément Rocher, Florence Lachenal, Stéphane Morisset, Christian Récher, Arnaud Pigneux, Amine Belhabri, Mauricette Michallet, Anne‐Sophie Michallet
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7175-7181 (2023)
Abstract Background Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low‐dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at the time of this stu
Externí odkaz:
https://doaj.org/article/63f3a6ecd43b4f86b0b0537085a06afc
Autor:
Louise Laloi, Natacha Chaumard Billotey, Pierre‐Yves Dumas, Franciane Paul, Alban Villate, Célestine Simand, Luc Fornecker, Florent Puisset, Sarah Bertoli, Marion Boissard Simonet, Kamel Laribi, Dyhia Houyou, Alberto Santagostino, Claire Michel, Gabrielle Roth Guepin, Elodie Guerineau, Reza Tabrizi, Mathilde Hunault, Aurélien Giltat, Eléonore Kaphan, Claude Bulabois, Elodie Cartet, Clément Rocher, Florence Lachenal, Stéphane Morisset, Christian Récher, Arnaud Pigneux, Amine Belhabri, Mauricette Michallet, Anne‐Sophie Michallet
Publikováno v:
Cancer Medicine. 12:7175-7181
Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low-dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at the time of this study, venetoclax was not